Clinical experience of Anidulafungin for the treatment of patients with documented Candidemia

Journal of Chemotherapy

Volumn 22, Issue 6, 2010, Pages 397-401

  Falcone, M ^a   Russo, A ^a   de Rosa, F G ^b   Pasero, D ^b   Toma, L ^c   Raponi, G ^a   Ghezzi, M C ^a   Venditti, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

^c Istituti Fisioterapici Ospedalieri   (Italy)

Author keywords

Anidulafungin; Candida albicans; Candidemia; Invasive candidiasis

Indexed keywords

ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; STEROID; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; HOSPITAL INFECTION; HUMAN; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; SEPSIS; SEPTIC SHOCK; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; CANDIDA; CLINICAL TRIAL; CROSS INFECTION; INDWELLING CATHETER; ISOLATION AND PURIFICATION; ITALY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; RETROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CATHETERS, INDWELLING; CROSS INFECTION; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; ITALY; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 79958259635     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.6.397     Document Type: Article

References (27)

1. Fridkln SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41: 1455-60.
2. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Ed-mond MB. Nosocomial bloodstream infections in US hospitals: analy-sis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
4. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Van-dercam B, et al. Candidemia in cancer patients: a prospective, multi-center surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28: 1071-9.
5. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
6. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
7. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007; 10: 121-30.
8. Rogers TR, Johnson EM, Munro C. Echinocandin antifungal drug resistance. J Invasive Fungal Infect 2007; 1: 99-105.
9. Bennett JE. Echinocandins for candidemia in adults without neu- tropenia. N Engl J Med 2006; 355: 1154-9.
10. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 3149-54.
11. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 5425-7.
12. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson- Moya L, Smietana J, et al. Comparison of caspofungin and ampho- tericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
13. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin versus fluconazole for invasive candidia- sis. N Engl J Med 2007; 356: 2472-82.
14. rd ed. 2007
15. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and manage- ment of intravascular catheter-related infection: 2009 Update by the In- fectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
16. Brielmaier BD, Casabar E, Kurtzeborn CM, McKinnon PS, Ritchie DJ. Early clinical experience with anidulafungin at a large terti- ary care medical center. Pharmacotherapy 2008; 28: 64-73.
17. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
18. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65:104251.
19. Zilberberg MD, Kollef MH, Arnold H, Labelle A, Micek ST, Kothari S, et al. Inappropriate empiric antifungal therapy for can- didemia in the ICU and hospital resource utilization: a retrospective co- hort study. BMC Infect Dis 2010; 10: 150.
20. Falcone M, Barzaghi N, Carosi G, Grossi P, Minoli L, Ravasio V, et al. Candida infective endocarditis: report of 15 cases from a prospec- tive multicenter study. Medicine (Baltimore) 2009; 88: 160-8
21. Katragkou A, Chatzimoschou A, Simitsopoulou M, Dalakiouri-dou M, Diza-Mataftsi E, Tsantali C, et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 2008; 52: 357-60.
22. Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. An- timicrob Agents Chemother 2008; 52: 2242-3.
23. Falcone M, Accarpio F, Venditti M, Vena A, Sibio S, Sammartino P, Di Giorgio A. Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal car- cinomatosis. J Antimicrob Chemother 20l0; 65:2266-7.
24. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, et al. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 2009; 53: 5102-7.
25. Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 2009; 53: 2382-91.
26. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
27. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-42.